Heterocyclic compound

Patent metadata

Field	Value
Publication number	US-10975043-B2
Application number	US-202016773720-A
Country	US
Kind code	B2
Filing date	Jan 27, 2020
Priority date	Oct 24, 2014
Publication date	Apr 13, 2021
Grant date	Apr 13, 2021

Abstract

Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.
A compound represented by the formula (I):

wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

First claim

The invention claimed is:

1. A method of preparing a compound represented by formula (I):

wherein ring A is a pyrazole ring, a pyridine ring, or a pyrimidine ring; X is CH 2 or O; and R is a hydrogen atom or a C 1-6 alkyl group;
the method comprising:
(a) performing an alkylation reaction; and
(b) performing a hydrolysis reaction.

2. The method of claim 1 , wherein the method comprises:
(a) performing the alkylation reaction to form a chemical bond with X; and
(b) performing the hydrolysis reaction of an ester or nitrile group.

Assignees

• Takeda Pharmaceuticals Co

Inventors

• Banno Yoshihiro
• Kamaura Masahiro
• Takami Kazuaki
• Fukuda Koichiro
• Sasaki Shigekazu

Classifications

• C12N15/09

  Recombinant DNA-technology · CPC title

• C07K14/47

  from mammals · CPC title

• C07D263/38

  attached in position 2 · CPC title

• C07D239/34 Primary

  One oxygen atom · CPC title

• C07D231/22 Primary

  with aryl radicals attached to ring nitrogen atoms · CPC title